Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

King Edward Medical University

Status and phase: Enrolling; Phase 4

Conditions: Acute Coronary Syndromes

Treatments: Drug: Rosuvastatin 20 mg/day; Drug: Atorvastatin 40 mg

Study type: Interventional

Funder types: Other

Identifiers

NCT06765265

508/RC/KEMU/13-11-2023

Details and patient eligibility

About

there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months

Full description

this randomized clinical trial will include 152 patients of acute coronary syndrome with normal Vitamin D levels. they will be randomized to receive either Atorvastatin or Rosuvastatin. After 6 months of therapy, the impact on Vitamin D levels will be checked

Enrollment: 152 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Acute Coronary Syndrome

25 OH-Vitamin D levels between 30-70ng/ml

Exclusion criteria

Hypercalcemia

hypocalcemia

pregnancy

lactation

hypersensitivity to statins

hypothyroidism

Deranged LFTs & RFTs

Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

152 participants in 2 patient groups

Atorvastatin

Active Comparator group

Description:

Atorvatstain 40mg OD

Treatment:

Drug: Atorvastatin 40 mg

Rosuvastatin

Experimental group

Description:

Rosuvastatin 20mg

Treatment:

Drug: Rosuvastatin 20 mg/day